Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
busulfan + etoposide + cytarabine
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The BEA regimen is a myeloablative conditioning chemotherapy regimen consisting of busulfan, etoposide, and cytarabine (Ara-C). It is primarily used as a conditioning regimen prior to autologous stem cell transplantation (ASCT) in patients with hematological malignancies, particularly acute myeloid leukemia (AML) in first complete remission (CR1). Busulfan acts as an alkylating agent that cross-links DNA, etoposide is a topoisomerase II inhibitor that induces DNA double-strand breaks, and cytarabine is a pyrimidine analog that inhibits DNA synthesis. Together, this combination provides potent myeloablation and anti-leukemic activity to eradicate residual disease before stem cell rescue.
- Other names
- BEABEA conditioningBEA conditioning regimenBEA regimenbusulfan, etoposide and cytarabinebusulfan, etoposide, and cytarabinecytarabine + etoposide + busulfanetoposide + cytarabine + busulfan
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on busulfan + etoposide + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on busulfan + etoposide + cytarabine.